

## Supplementary Figure Legends




Figure S1

**Supplementary Fig 1.** Oral *S. typhimurium* infection induces mouse enteritis and system infection. C57BL/6 mice were infected orally with *S. typhimurium* ( $1 \times 10^5$ ) or mock-infected with Luria-Bertani (LB). Weight loss was evaluated at various time points post-infection (n = 5) (A). Hematoxylin and eosin (H&E)-stained sections of small intestines from infected mice (B). Bacterial loads of the liver, spleen, and MLN were determined by LB plate assay (n = 6) (C). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, compared with the group on day 0.





Figure S2

**Supplementary Fig 2.** Phenotype and activation of macrophage in the Lamina propria of *S. typhimurium*-infected mice. The expression of CD80, CD40, MHC-II and ROS, as well as intracellular TNF- $\alpha$  and IL-1 $\beta$  on/in F4/80<sup>+</sup>CD11b<sup>+</sup> macrophages was detected by FACS and statistically analyzed. Data are representative of three independent experiments (means $\pm$ SD). \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, compared with the LB group.



**Figure S3**

**Supplementary Fig 3.** The *in vivo* depletion efficiency of CD4<sup>+</sup>T, CD8<sup>+</sup>T, macrophages, and NK cells. Depleting antibodies ( $\alpha$ -CD4,  $\alpha$ -CD8,  $\alpha$ -NK1.1) and  $Cl_2$ MDP-liposome were injected *i.p.* into C57BL/6 mice. Three days later, the removal efficiency was detected by FACS.




Fig. S4

**Supplementary Fig 4.** CD4<sup>+</sup>T cells depletion has no effect on the proportion of intestinal lamina propria neutrophils during *S. typhimurium* infection. α-CD4 antibody were injected *i.p.* into C57BL/6 mice. Three days later, mice were orally infected with *S. typhimurium*. Five days later, the percentage of intestinal neutrophils were detected by FACS. The LP leukocytes were first gated (FSC-H vs. FSC-H) and further stained with 7-AAD to exclude dead cells, leukocytes were then selected by the expression of CD45. The percentage of Gr1<sup>+</sup>CD11b<sup>+</sup>neutrophils were determined by flow cytometry. Data are representative of three independent experiments (means ± SD). \*\*\*p < 0.001, compared with the control group.





Figure S5

**Supplementary Fig 5.** Depletion of CD4<sup>+</sup>T cells did not impair the production of TNF- $\alpha$  and ROS by intestinal macrophages during *S. typhimurium* infection. Mice were injected *i.p.* with anti-CD4 antibodies. Three days later, the treated mice were orally infected with *S. typhimurium*. Five days after infection, the small intestinal LP lymphocytes were isolated and the production of TNF- $\alpha$  (A) and ROS (B) by F4/80+CD11c<sup>+</sup> macrophages was detected by flow cytometry. Data are expressed as the means  $\pm$  SD of at least three independent experiments. \* $p < 0.05$ .



**Figure S6**

**Supplementary Fig 6.** Tim-3–galectin-9 pathway is involved in the induction of CD4<sup>+</sup>T cell apoptosis. LP macrophages were infected with *S. typhimurium* (MOI=10:1). One hour later, the expression of galectin-9 on macrophages was determined by immunofluorescence staining. Green and red colors represent *S. typhimurium* and galectin-9, respectively; blue represents nuclei. (A). CD4<sup>+</sup>T cells isolated from LP lymphocytes by MACS were co-cultured with *S. typhimurium*-infected macrophages. The production of IFN- $\gamma$  and expression of CD44 by CD4<sup>+</sup>T cells were measured by FACS (B). The apoptosis of CD4<sup>+</sup>T cells were measured by Annexin-V/PI double staining methods (C). Data are representative of three independent experiments.

**Supplementary Table 1. Antibodies used for flow cytometry.**

<b>Antibody</b>	<b>Company</b>	<b>Clone</b>
NK1.1	BD Biosciences	PK136
CD4	eBioscience	GK1.5
CD8	Biologend	53-5.8
CD11c	Biologend	N418
CD40	eBioscience	HM40.3
CD80	eBioscience	16-10A1
CD69	eBioscience	H1.2F3
CD44	eBioscience	IM7
IFN- $\gamma$	eBioscience	XMG1.2
IL-1 $\beta$	R&D Systems	166931
CD11b	Biologend	M1/70
F4/80	eBioscience	BM8
Tim-3	eBioscience	RMT3-23
MHC II	Biologend	M5/114.15.2
CD3e	Biologend	145-2c11
galectin-9	eBioscience	RG9-35
Ly-6C	ebioscience	HK1.4
CD45	BD Biosciences	30-F11
Siglec-F	BD Biosciences	E50-2440
Ly-6G	Biologend	1A8
Gr1	Biologend	RB6-8C5